Trevi Therapeutics (TRVI) Set to Announce Quarterly Earnings on Tuesday

Trevi Therapeutics (NASDAQ:TRVI) will issue its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Wednesday, March 20th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.02. On average, analysts expect Trevi Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Trevi Therapeutics Stock Down 2.4 %

Shares of NASDAQ:TRVI opened at $2.86 on Thursday. The business has a 50 day moving average price of $3.01 and a 200 day moving average price of $2.02. Trevi Therapeutics has a twelve month low of $0.97 and a twelve month high of $4.00. The company has a market cap of $201.43 million, a price-to-earnings ratio of -9.86 and a beta of 0.91.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Trevi Therapeutics in a report on Tuesday, April 9th. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 target price on shares of Trevi Therapeutics in a research report on Thursday, March 21st.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.